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ABSTRACT
Introduction In patients with myocardial infarction, the 
decision to treat a nonculprit lesion is generally based 
on its physiological significance. However, deferral of 
revascularisation based on nonischaemic fractional flow 
reserve (FFR) values in these patients results in less 
favourable outcomes compared with patients with stable 
coronary artery disease, potentially caused by vulnerable 
nonculprit lesions. Intravascular optical coherence 
tomography (OCT) imaging allows for in vivo morphological 
assessment of plaque ‘vulnerability’ and might aid in the 
detection of FFR- negative lesions at high risk for recurrent 
events.
Methods and analysis The PECTUS- obs study is an 
international multicentre prospective observational study that 
aims to relate OCT- derived vulnerable plaque characteristics 
of nonflow limiting, nonculprit lesions to clinical outcome 
in patients with myocardial infarction. A total of 438 
patients presenting with myocardial infarction (ST- elevation 
myocardial infarction and non- ST- elevation myocardial 
infarction) will undergo OCT- imaging of any FFR- negative 
nonculprit lesion for detection of plaque vulnerability. The 
primary study endpoint is a composite of major adverse 
cardiovascular events (all- cause mortality, nonfatal 
myocardial infarction or unplanned revascularisation) at 
2- year follow- up. Secondary endpoints will be the same 
composite at 1- year and 5- year follow- up, target vessel 
failure, target vessel revascularisation, target lesion failure 
and target lesion revascularisation.
Ethics and dissemination This study has been approved 
by the Medical Ethics Committee of the region Arnhem- 
Nijmegen. The results of this study will be disseminated 
in a main paper and additional papers with subgroup 
analyses.
Trial registration number NCT03857971.
INTRODUCTION
In patients presenting with myocardial infarc-
tion (MI), percutaneous coronary interven-
tion (PCI) of the culprit lesion is the standard 
method of treatment.1 A high percentage 
of these patients have additional lesions at 
different sites in the coronary arteries, not 
responsible for the acute event. The optimal 
treatment of these nonculprit lesions is subject 
of extensive research, because their presence 
confers a greater risk of future major adverse 
cardiac events (MACE).2 3 Recent studies 
showed that complete revascularisation 
Strengths and limitations of this study
 ► The PECTUS- obs is the first prospective study to 
assess the incremental value of optical coher-
ence tomography (OCT) imaging of fractional flow 
reserve- deferred nonculprit lesions in patients pre-
senting with myocardial infarction (MI).
 ► OCT is the only imaging modality with a spatial res-
olution high enough to truly measure fibrous cap 
thickness, the plaque feature most associated with 
adverse events.
 ► In PECTUS- obs, OCT imaging will only be performed 
at baseline. However, any new MI or revascularisa-
tion will be allocated to a specific coronary vessel 
and lesion by comparison of the baseline and follow- 
up angiograms.
 ► If intracoronary imaging with OCT is able to identify 
lesions associated with worse outcome, this might 
warrant studies on focal or pharmacological inter-
vention of OCT- determined vulnerable plaques.
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results in improved outcomes compared with treat-
ment of the culprit lesion only.4–6 However, nonselective 
revascularisation of all nonculprit lesions may lead to 
overtreatment.
The selection of nonculprit lesions qualifying for revas-
cularisation is often based on whether a lesion causes 
ischaemia, as determined by invasive measurements 
such as the fractional flow reserve (FFR).7 In patients 
with stable coronary artery disease (CAD), FFR- guided 
complete revascularisation results in better outcomes 
compared with angiography- guided complete revascu-
larisation.8 Nevertheless, the MACE rates at longer term 
follow- up remain significant in the presence of nonsig-
nificant CAD.9 In patients presenting with MI, this recur-
rence rate of ischaemic events is even higher.10 A recent 
study demonstrated a MACE rate of 23% in patients with 
acute coronary syndrome (ACS) versus 11% in patients 
with stable CAD at 3.4- year follow- up, after FFR- based 
deferral of revascularisation. Among these patients with 
ACS, especially those presenting with non- ST- elevation 
myocardial infarction (NSTEMI) had a high event rate 
(42%).11
Apart from coronary physiology, the structural compo-
nents of nonculprit lesions might provide other markers 
for future adverse events. Autopsy studies have granted 
insight into the lesion characteristics that are associated 
with plaque rupture and subsequent MI or sudden death. 
These lesions tend to contain a large lipid pool with a 
thin overlying fibrous cap and display a large degree of 
outward remodelling.12 13 These ‘thin- cap fibroather-
omas’ (TCFA) are more frequently observed in both 
culprit and nonculprit lesions of patients presenting with 
MI than in patients presenting with stable CAD and are 
a strong predictor of culprit plaque rupture in ACS.14–17 
Therefore, screening for vulnerable plaques on top of 
physiological measurements should be evaluated for 
nonculprit lesions.
Analysis of lesion composition can be performed in 
vivo with the use of intravascular imaging techniques 
such as intravascular ultrasound (IVUS), near infrared 
spectroscopy (NIRS) and optical coherence tomog-
raphy (OCT).18 Prospective studies using IVUS and 
NIRS showed that identification of lesions at higher risk 
for future events is feasible.19 20 However, OCT might 
prove more suitable for this purpose, due to its specific 
characteristics. OCT has a 10–20 times higher spatial 
resolution than IVUS, allowing for better detection of 
TCFA. Moreover, a complete acquisition of a coronary 
segment can be provided within a couple of seconds, 
with a single pullback. Finally, (semi)automated anal-
ysis of images is more feasible due to the high resolu-
tion of the acquired images.21 Nevertheless, OCT has 
yet to be prospectively validated for its ability to identify 
lesions at risk for future MACE in patients with MI.
For future studies on potential preventive revascular-
isation or more aggressive pharmacological therapy in 
patients with high- risk lesions, prospective studies with 
clinical outcomes are imperative. In the PECTUS- obs 
study, we aim to relate OCT- derived plaque characteris-
tics of not significantly flow- limiting, nonculprit lesions 
to clinical outcome in patients presenting with MI.
METHODS AND ANALYSIS
Overview
The PECTUS- obs study is designed as an international 
multicentre prospective observational study. Eligible 
patients have to undergo an index coronary angiog-
raphy (CAG) during hospitalisation for an acute MI, 
which reveals one or more nonculprit lesions acces-
sible for imaging with OCT. FFR measurements of these 
nonculprit lesions are made during the same index 
procedure or during a staged procedure. Any FFR- 
nonsignificant lesions are subsequently imaged with 
OCT. Additional criteria are listed in table 1. A total of 
438 patients will be included. A flowchart of the study 
design is depicted in figure 1.
Patients and enrolment
Patients presenting with MI (ST- elevation and non- ST- 
elevation) are screened for potential inclusion in the 
study. Patients are treated according to the current guide-
lines for the management of ACS, including referral for 
CAG and (potential) PCI of the culprit artery. In case of 
one or more nonculprit lesions of intermediate stenosis 
(30%–90%), clinically indicated FFR measurements 
are performed in order to determine whether these 
nonculprit stenoses are haemodynamically significant 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Clinical
 ► Age≥18 years
 ► Hospitalisation with a 
STEMI or NSTEMI for 
which patient is subjected 
to invasive coronary 




 ► Haemodynamic instability, 
respiratory failure or Killip 
class ≥3 at time of inclusion.
 ► Previous CABG.
 ► Indication for 
revascularisation by CABG.
 ► Estimated life expectancy 
<3 year.
Angiographical
 ► Patient has ≥1 non- 
culprit, target lesion(s) 
with following additional 
characteristics:
 – Lesion has visual 
stenosis of 30%–90%.
 – Lesion is non- 
obstructive (FFR 
>0.80).
 – Lesion is not in- stent 
restenosis.
Angiographical
 ► Anatomy of target lesion(s) is 
unsuitable for OCT catheter 
crossing or imaging (aorta- 
ostial lesions, too small 
diameter segment, severe 
calcifications, chronic total 
occlusion, distal lesions 
prohibiting OCT imaging).
CABG, coronary artery bypass grafting; FFR, fractional flow 
reserve; NSTEMI, non- ST- elevation myocardial infarction; OCT, 
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(figure 2). If a stenosis is nonsignificant (FFR >0.8) and 
the patient is eligible for inclusion based on the criteria 
listed in table 1, informed consent is obtained for partic-
ipation in the study. If the FFR is ≤0.80 (haemodynami-
cally significant), the patient is revascularised according 
to the current therapeutic guidelines.
Timing of FFR measurements and informed consent
FFR measurements of nonculprit lesions are performed 
either during the index CAG or during a staged proce-
dure within 6 weeks. If nonculprit lesions are assessed 
during the index procedure, patients are approached 
for participation after revascularisation of the culprit 
artery and any FFR measurements. After oral consent, 
the OCT pullbacks are performed of all FFR- negative 
stenoses. Written informed consent is acquired after 
the procedure. If nonculprit lesion will be evaluated 
during a staged procedure, written informed consent is 
acquired prior to the staged procedure.
OCT imaging
After administration of intracoronary nitrates, an OCT 
pullback of the target lesion is acquired using the 
FD- OCT ILUMIEN system (Abbott, USA) over a normal 
0.14” guidewire or pressure wire. The OCT system is CE 
marked and deployed as intended by the manufacturer. 
For effective clearing of blood from the imaging field, 
angiographic contrast media is injected. For the average 
coronary vessel 14 mL of contrast media is injected using 
an automated injector at a rate of 4 mL/s at 300 PSI. The 
contrast amount and/or infusion rate can be adjusted 
proportionally to coronary artery diameter to ensure 
good image quality. The segment of interest is scanned 
with a pull- back speed of 18 mm/s (54 mm segment). 
The entire OCT- pullback is recorded simultaneously with 
fluoroscopy to ensure that the anatomy of the OCT pull-
back can be linked to the angiogram. Multiple runs are 
allowed in case of poor image quality. In case of multiple 
target lesions eligible for OCT imaging, OCT imaging of 
each target lesion is performed. OCT images are not used 
for procedural guidance.
Blood sampling
During CAG, after OCT imaging is performed, 10 mL 
of blood is drawn from the arterial sheath. This blood is 
used for the determination of biomarkers for plaque or 
patient vulnerability.
OCT-imaging analysis
OCT images and corresponding angiograms are analysed 
offline by trained personnel in an OCT core laboratory. 
Evaluation of the images is based on tissue characteris-
tics as previously described in OCT expert consensus 
papers.22 23 A plaque is deemed ‘vulnerable’ if it contains 
two of the following characteristics: a lipid arc of ≥90°, 
a cap thickness of <65 µm and either cap rupture or 
thrombus formation. An example of a vulnerable plaque 
with a lipid arc of >90° and a cap thickness of <65 µm is 
shown in figure 2.
Study endpoints
The primary study endpoint consists of a composite of 
major adverse cardiovascular events (all- cause mortality, 
nonfatal MI (STEMI or NSTEMI) or unplanned revas-
cularisation) at 2- year follow- up in patients with a 
vulnerable plaque as compared with patients without a 
vulnerable plaque. Secondary endpoints are: MACE at 
1- year and 5- year follow- up, target vessel failure, target 
vessel revascularisation, target lesion failure and target 
lesion revascularisation.
Exploratory analyses
Additional exploratory analyses will be performed by 
comparing nonculprit plaque characteristics in patients 
presenting with STEMI versus NSTEMI, in diabetic 
versus nondiabetic patients, and in male versus female 
patients. Plaque morphology will also be related to 
angiographic lesion features. Moreover, in order to 
accelerate the process of OCT imaging interpretation, 
automated detection of morphological features asso-
ciated with MACE will be developed with the use of 
machine learning.
Figure 1 PECTUS- obs flowchart. CAG, coronary 
angiography, FFR, fractional flow reserve, NSTEMI, non- 
ST- elevation myocardial infarction, OCT, optical coherence 
tomography, STEMI, ST- elevation myocardial infarction
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Follow-up and endpoint adjudication
At 1- year, 2- year and 5- year patients are followed- up by 
telephone contact. Medical records (including coro-
nary angiograms) from participating centres, general 
practitioners and other medical centres are used for 
the verification of endpoints. Additionally, mortality 
data are obtained from national registries. A clinical 
event adjudication committee blinded to OCT data 
will assess endpoints, separate cardiovascular mortality 
from noncardiovascular mortality, and allocate any new 
MI or revascularisation to a specific coronary vessel 
and lesion by comparison of the baseline and follow- up 
angiograms.
Sample size calculation and statistical analysis
The total sample size is calculated at 438 patients. The 
sample size is calculated to provide 90% power with 
a one- sided alpha of 0.025 to identify OCT variables 
associated with nonculprit lesion- related major adverse 
cardiovascular events. It is based on the assumption that 
high- risk OCT- defined vulnerable plaques are identi-
fied in 60% of targeted lesions, on a total event rate 
of 25% after 2 years in FFR- deferred lesions in patients 
with MI,11 24 and an expected HR of at least 3.5 for OCT 
defined vulnerable plaques.19 A power of 80% is main-
tained when the HR is lower than expected, but at least 
2.0, or when the event rate is lower than expected but at 
least 10%. Estimated loss to follow- up is 5%, and inade-
quate OCT scans prohibiting assessment of vulnerable 
plaque characteristics are expected in 5% of cases.
At 2- year follow- up, MACE in patients with vulner-
able plaque characteristics will be compared with 
patients without vulnerable plaque characteristics in 
terms of HR. Descriptives will be expressed as mean±SD 
(continuous data) or as frequencies and proportions 
(categorical data). Continuous variables are presented 
as mean SD if normally distributed or median (IQR) 
if not normally distributed. Categorical variables are 
presented as counts and percentages. Continuous vari-
ables are compared between groups using the Student 
t- test or its nonparametric equivalent Mann- Whitney U 
test. The χ2 test (for comparison of proportions) will 
be performed where appropriate. Multivariate Cox 
proportional hazard regression will be used to correct 
for differences in baseline characteristics like age, sex, 
diabetes mellitus, hypertension, dyslipidaemia, indica-
tion for CAG (STEMI vs NSTEMI), history of MI and 
history of PCI if necessary. All calculations will be gener-
ated by statistical package for social sciences software 
(SPSS Statistics V.24; IBM, Armonk, New York).
Patient and public involvement
Patients were not involved in the design of this study.
CURRENT STATUS
Recruitment commenced in December 2018 and was 
completed in September 2020. With 2- year follow- up 
for the primary endpoint, reporting on the study is 
expected in the beginning of 2023.
Figure 2 Lesion assessment in the PECTUS- obs study. Upper left: CAG shows a non- culprit lesion (red box) in the 
proximal RCA. The radiopaque marker inside the vessel at the location of the lesion represents the OCT lens. Lower left: FFR 
measurement of the lesion reveals that it is nonflow- limiting (FFR=0.94). Right: OCT imaging shows an atherosclerotic plaque 
with a lipid arc of 200° and a minimal fibrous cap thickness of 4 µm. This lesion therefore meets the criteria for a vulnerable 
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DISCUSSION
The PECTUS- obs study was designed to investigate the 
association between OCT- determined characteristics 
of plaque vulnerability and future MACE in nonflow- 
limiting, nonculprit lesions of patients presenting with 
MI.
In current practice, the decision whether or not to 
preventively treat a nonculprit lesion is primarily based 
on its physiological significance. Although this strategy 
is clearly superior in stable CAD, it has yet to be proven 
in patients presenting with MI.8 In STEMI, several large 
randomised trials have shown that FFR- guided complete 
revascularisation results in fewer MACE compared with 
culprit- only revascularisation.25 26 However, randomised 
controlled trials directly comparing FFR- guided complete 
revascularisation with angiography- guided complete 
revascularisation in STEMI have not yet been conducted, 
and the only two studies showing a reduction in major 
clinical endpoints (death and MI) after nonculprit 
revascularisation were actually guided by angiography 
rather than physiology.4 27 For patients with NSTEMI, 
the evidence is even more scarce. In the only available 
randomised trial, the FAMOUS- NSTEMI trial, MACE rates 
at 1- year follow- up did not differ between patients with 
FFR- guided and angiography guided treatment (8.0% vs 
8.6%).28 However, this study was primarily designed to 
evaluate the effect of FFR measurements on management 
decisions and was not powered to assess between- group 
differences in clinical outcomes. The ongoing SLIM trial 
(NCT03562572) aims to address this gap in knowledge. 
Nevertheless, even if FFR- guided complete revascularisa-
tion proves superior in patients with MI, the long- term 
MACE rate remains significant.11 It, therefore, remains 
unclear if nonculprit lesion selection based solely on FFR 
is sufficient, or if other features like plaque morphology 
need to be taken into account.
In previous prospective intravascular imaging studies, 
plaque morphology has consistently been analysed using 
IVUS. In the PROSPECT study, 697 patients with ACS 
were subjected to three- vessel radiofrequency (RF)- 
IVUS imaging.19 All atherosclerotic lesions found in 
the recordings were subsequently analysed for plaque 
composition. After a median follow- up of 3.4 years, 
researchers found that nonculprit lesions with a minimal 
lumen area (MLA) of 4.0 mm² or less, a plaque burden of 
70% or greater and those classified as TCFA were associ-
ated with a higher rate of MACE. Following PROSPECT, 
several other studies confirmed the association between 
RF- IVUS- derived vulnerable plaques and MACE.29 30 The 
main limitation of RF- IVUS when it comes to identifying 
TCFAs is its poor resolution. In the landmark study by 
Burke et al, 95% of ruptured plaques had a fibrous cap 
thickness of less than 65 µm.31 More recent reports found 
that cap thickness of lesions classified as TCFA ranges 
from 54 µm to 84 µm.32 RF- IVUS has a spatial resolution 
of approximately 150 µm, leaving it below the detection 
range for cap thickness in these lesions. Moreover, of all 
plaque features that are related with adverse outcomes, 
cap thickness seems to be the most important.32 As 
mentioned earlier, with a spatial resolution of approxi-
mately 10 µm, we expect that OCT is more suitable for 
identifying TCFA. However, prospective data on the asso-
ciation between OCT- derived vulnerable plaques and 
future events are limited. Recently, the arsenal of inva-
sive imaging modalities was broadened by NIRS. The 
ATHEROREMO- NIRS study proved that NIRS- derived 
lipid core burden index was associated with MACE at a 
patient level, whereas the LRP study later expanded on 
this observation by showing that NIRS can also identify 
plaques vulnerable to future MACE.20 33
The CLIMA study investigated the association between 
a predefined combination of four high- risk plaque 
features (MLA <3.5 mm², fibrous cap thickness <75 µm, 
a lipid arc >180° and the presence of macrophage clus-
ters) and clinical events in patients that underwent OCT 
imaging of the proximal left anterior descending artery 
(LAD).34 This combination of features proved to be 
an independent predictor of events with a HR of 7.54. 
However, this study differed from the current design in 
several aspects. Even though CLIMA involved prospec-
tive follow- up, patients were only included after under-
going OCT imaging for a clinical indication. Moreover, 
imaging had to be performed on a predefined segment 
(proximal- mid LAD) that could not include, or be adja-
cent to, a stenosis of ≥50%. Therefore, OCT- imaging, in 
this study, was used to screen a fixed vessel segment that 
was relatively free of stenosis, whereas the PECTUS- obs 
evaluates targeted OCT imaging of angiographically 
determined stenoses of intermediate severity that are 
FFR- negative.
The COMBINE study shares more similarities with 
the current study design.35 In this prospective registry 
of patients with diabetes requiring CAG, OCT imaging 
of FFR nonflow limiting lesions revealed that patients 
with TCFAs had increased target lesion- related MACE 
compared with patients without TCFAs (13.3% vs 9.7%) at 
18- month follow- up.36 In this study, however, only 25% of 
included patients had presented with an ACS at baseline.
The current prospective observational study could 
serve as an important step towards OCT imaging- guided 
treatment of nonculprit lesions. However, randomised 
trials need to be conducted in order to evaluate the effi-
cacy of OCT- based interventions. This was attempted in 
a previous trial in which pre- emptive stenting of FFR- 
negative OCT- identified vulnerable plaques with ABSORB 
bioresorbable vascular scaffolds (BVS) was compared with 
optimal medicinal therapy alone.37 Unfortunately this 
trial was stopped prematurely because the ABSORB BVS 
was retracted from the market. The currently enrolling 
PREVENT trial (NCT02316886) also aims to evaluate 
imaging- guided preemptive stenting, although it uses 
IVUS and NIRS in addition to OCT. Finally, the recently 
published PROSPECT ABSORB trial showed good safety 
outcomes after IVUS/NIRS- guided pre- emptive stenting, 
while it was not powered for clinical endpoints.38
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CONCLUSION
The PECTUS- obs is the first prospective study to assess 
the incremental value of OCT imaging of FFR- deferred 
nonculprit lesions in patients presenting with MI. If intra-
coronary imaging with OCT is able to identify lesions 
associated with worse outcome, this might warrant 
studies on focal or pharmacological intervention of OCT- 
determined vulnerable plaques.
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This study has been approved by the Medical Ethics 
Committee of the region Arnhem- Nijmegen (file number 
2018-4763). All participants gave informed consent prior 
to inclusion in the study. The results of this study will be 
disseminated in a main paper and additional papers with 
subgroup analyses.
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